{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T14:22:58Z","timestamp":1724854978523},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,19]]},"DOI":"10.7759\/cureus.67257","type":"journal-article","created":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T06:54:04Z","timestamp":1724136844000},"source":"Crossref","is-referenced-by-count":0,"title":["Safety Surveillance of Covishield Vaccine-Associated Adverse Events During the COVID-19 Pandemic: A Retrospective Longitudinal Study"],"prefix":"10.7759","author":[{"given":"Shilpa","family":"Chaudhary","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puja","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gopal","family":"Vishwas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Girish G","family":"Meshram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit","family":"Dhaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minakshi","family":"Garg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO Director\u2010General\u2019s remarks at the media briefing on 2019\u2010nCoV on 11 March 2020. (2020). Accessed. May 18,2022: https:\/\/www.who.int\/director-general\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1712187","article-title":"Epidemiology of COVID-19","volume":"11","author":"Dhar Chowdhury S","year":"2020","unstructured":"Dhar Chowdhury S, Oommen AM. Epidemiology of COVID-19. J Dig Endosc. 2020, 11:3-7. 10.1055\/s-0040-1712187","journal-title":"J Dig Endosc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/978-981-15-5936-5_1","article-title":"An introduction to COVID-19","author":"Fong SJ","year":"2021","unstructured":"Fong SJ, Dey N, Chaki J. An introduction to COVID-19. Artificial Intelligence for Coronavirus Outbreak. Springer, Singapore; 2021. 1-22. 10.1007\/978-981-15-5936-5_1"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"Wu F","year":"2020","unstructured":"Wu F, Zhao S, Yu B, et al.. A new coronavirus associated with human respiratory disease in China. Nature. 2020, 579:265-9. 10.1038\/s41586-020-2008-3","journal-title":"Nature"},{"key":"ref5","unstructured":"World Health Organization. WHO coronavirus dashboard. (2022). Accessed. June 22, 2022: https:\/\/covid19.who.int.."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.5005\/jp-journals-10055-0111","article-title":"A study of COVID-19 vaccine (Covishield) pharmacovigilance in primary healthcare workers in Punjab, India","volume":"5","author":"Singh N","year":"2021","unstructured":"Singh N, Singh J, Bhandari V, et al.. A study of COVID-19 vaccine (Covishield) pharmacovigilance in primary healthcare workers in Punjab, India. AMEIs Curr Trends Diagn Treat. 2021, 5:6-11. 10.5005\/jp-journals-10055-0111","journal-title":"AMEIs Curr Trends Diagn Treat"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvacx.2022.100210","article-title":"Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India","volume":"12","author":"T Sathyapalan D","year":"2022","unstructured":"T Sathyapalan D, Moni M, Prasanna P, et al.. Adverse events associated with Covishield vaccination among healthcare workers in a tertiary hospital in South India. Vaccine X. 2022, 12:100210. 10.1016\/j.jvacx.2022.100210","journal-title":"Vaccine X"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-022-09265-0","article-title":"Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review","volume":"70","author":"Das S","year":"2022","unstructured":"Das S, Kar SS, Samanta S, Banerjee J, Giri B, Dash SK. Immunogenic and reactogenic efficacy of Covaxin and Covishield: a comparative review. Immunol Res. 2022, 70:289-315. 10.1007\/s12026-022-09265-0","journal-title":"Immunol Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00680-0","article-title":"Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses","volume":"22","author":"Thiruvengadam R","year":"2022","unstructured":"Thiruvengadam R, Awasthi A, Medigeshi G, et al.. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses. Lancet Infect Dis. 2022, 22:473-82. 10.1016\/S1473-3099(21)00680-0","journal-title":"Lancet Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.lansea.2023.100141","article-title":"Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD\u2122) and BBV152 (COVAXIN\u00ae): a non-inferiority phase 4, participant and observer-blinded, randomised study","volume":"12","author":"Rose W","year":"2023","unstructured":"Rose W, Raju R, Babji S, et al.. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD\u2122) and BBV152 (COVAXIN\u00ae): a non-inferiority phase 4, participant and observer-blinded, randomised study. Lancet Reg Health Southeast Asia. 2023, 12:100141. 10.1016\/j.lansea.2023.100141","journal-title":"Lancet Reg Health Southeast Asia"},{"key":"ref11","unstructured":"Ministry of Health and Family Welfare, Government of India. CoWIN dashboard. (2022). Accessed. July 12, 2022: https:\/\/dashboard.cowin.gov.in."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey M","year":"2021","unstructured":"Voysey M, Costa Clemens SA, Madhi SA, et al.. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021, 397:881-91. 10.1016\/S0140-6736(21)00432-3","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.101218","article-title":"A phase 2\/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India","volume":"42","author":"Kulkarni PS","year":"2021","unstructured":"Kulkarni PS, Padmapriyadarsini C, Vekemans J, et al.. A phase 2\/3, participant-blind, observer-blind, randomised, controlled study to assess the safety and immunogenicity of SII-ChAdOx1 nCoV-19 (COVID-19 vaccine) in adults in India. EClinicalMedicine. 2021, 42:101218. 10.1016\/j.eclinm.2021.101218","journal-title":"EClinicalMedicine"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu Q","year":"2021","unstructured":"Wu Q, Dudley MZ, Chen X, et al.. Evaluation of the safety profile of COVID-19 vaccines: a rapid review. BMC Med. 2021, 19:173. 10.1186\/s12916-021-02059-5","journal-title":"BMC Med"},{"key":"ref15","unstructured":"World Health Organization. The use of the WHO-UMC system for standardized case causality assessment. (2022). Accessed. December 15, 2022: https:\/\/www.who.int\/docs\/default-source\/medicines\/pharmacovigilance\/whocausality-assessment.pdf."},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2023.02.004","article-title":"Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: an analysis of nationwide causality assessment from India","volume":"75","author":"Gandhi AP","year":"2023","unstructured":"Gandhi AP, Venkatesh U, Murali N. Serious adverse event following immunization and thromboembolic events associated with COVID19 vaccination: an analysis of nationwide causality assessment from India. Indian Heart J. 2023, 75:139-44. 10.1016\/j.ihj.2023.02.004","journal-title":"Indian Heart J"},{"key":"ref17","unstructured":"2K serious cases of AEFI, 0.004% of 123 crore of shots given. government. (2021). Accessed: January 23, 2022: https:\/\/timesofindia.indiatimes.com\/india\/2k-serious-cases-of-aefi-0-004-of-123-crore-ofshots-given-government\/articl...."},{"key":"ref18","unstructured":"Public Health Ontario. Adverse events following immunization for COVID-19 in Ontario. December 13, 2020 to December 31. (2023). Accessed: January 25, 2023: https:\/\/www.publichealthontario.ca\/-\/media\/documents\/ncov\/epi\/covid-19-aefi-report."},{"key":"ref19","unstructured":"Pan American Health Organization. (2021). Accessed. December 23, 2022: https:\/\/covid-19pharmacovigilance.paho.org\/img\/recursos\/61dd7bb2207db780093bd4a54.pdf."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.11606\/s1518-8787.2021055003734","article-title":"Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais","volume":"55","author":"Silva RB","year":"2021","unstructured":"Silva RB, Silva TP, Sato AP, Lana FC, Gusm\u00e3o JD, Souza JF, Matozinhos FP. Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais. Rev Saude Publica. 2021, 55:66. 10.11606\/s1518-8787.2021055003734","journal-title":"Rev Saude Publica"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_885_22","article-title":"Adverse effects after first and second dose of covishield and covaxin: a longitudinal study","volume":"11","author":"Mittal A","year":"2022","unstructured":"Mittal A, Jain B, Varshney AM, Garg G, Sachan D, Singh RB. Adverse effects after first and second dose of covishield and covaxin: a longitudinal study. J Family Med Prim Care. 2022, 11:7339-45. 10.4103\/jfmpc.jfmpc_885_22","journal-title":"J Family Med Prim Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.37821\/ruhsjhs.6.4.2021.388","article-title":"Pattern of adverse drug reactions to Covishield vaccine among the faculty of a tertiary care teaching hospital in Jaipur city","volume":"6","author":"Kapadia R","year":"2021","unstructured":"Kapadia R, Jain M, Sharma L, et al.. Pattern of adverse drug reactions to Covishield vaccine among the faculty of a tertiary care teaching hospital in Jaipur city. RUHS J Health Sci. 2021, 6:4. 10.37821\/ruhsjhs.6.4.2021.388","journal-title":"RUHS J Health Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine","volume":"384","author":"Sadoff J","year":"2021","unstructured":"Sadoff J, Le Gars M, Shukarev G, et al.. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021, 384:1824-35. 10.1056\/NEJMoa2034201","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/272670-safety-surveillance-of-covishield-vaccine-associated-adverse-events-during-the-covid-19-pandemic-a-retrospective-longitudinal-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,20]],"date-time":"2024-08-20T06:54:15Z","timestamp":1724136855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/272670-safety-surveillance-of-covishield-vaccine-associated-adverse-events-during-the-covid-19-pandemic-a-retrospective-longitudinal-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.67257","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,19]]}}}